Pipeline
Crossfire has several candidates in different stages of development, aimed at improving therapeutic efficacy in non-responding patient populations.
Products
DISCOVERY
PRECLINICAL
PHASE I/II
2nd and 3rd program
2nd and 3rd program
DAC (Degrader Antibody Conjugate) platform
DAC (Degrader Antibody Conjugate) platform